E

Evofem Biosciences Inc
OTC:EVFM

Watchlist Manager
Evofem Biosciences Inc
OTC:EVFM
Watchlist
Price: 0.009 USD Market Closed
Market Cap: $1.1m

Net Margin

348.7%
Current
Improving
by 114.2%
vs 3-y average of 234.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
348.7%
=
Net Income
$47.5m
/
Revenue
$16m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
348.7%
=
Net Income
$47.5m
/
Revenue
$16m

Peer Comparison

Country Company Market Cap Net
Margin
US
Evofem Biosciences Inc
F:1AQ1
65.8m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Higher than 99% of companies in the United States of America
Percentile
99th
Based on 15 072 companies
99th percentile
296.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Evofem Biosciences Inc
Glance View

Market Cap
1.1m USD
Industry
Pharmaceuticals

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

EVFM Intrinsic Value
Not Available
E
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
348.7%
=
Net Income
$47.5m
/
Revenue
$16m
What is Evofem Biosciences Inc's current Net Margin?

The current Net Margin for Evofem Biosciences Inc is 348.7%, which is above its 3-year median of 234.5%.

How has Net Margin changed over time?

Over the last 1 years, Evofem Biosciences Inc’s Net Margin has increased from -285.3% to 348.7%. During this period, it reached a low of -285.3% on Mar 3, 2023 and a high of 494.3% on Jun 30, 2023.

Back to Top